|Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players|
The once-daily tablets -- which are also approved to treat pancreatic neuroendocrine tumors and gastrointestinal stromal tumors -- were pitted against interferon-alfa in trials and demonstrated a better-than-doubling of median progression-free survival ...
DailyFinance - Mon, 06 May 2013 02:47
|Exciting Biotech Stocks Investing Ideas Have Explosive Potential|
... its unpartnered proteasome inhibitor Kyprolis (carfilzomib) for multiple myeloma, and its multikinase inhibitor Stivarga (regorafenib) for metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor, which is being developed by Bayer ...
The Market Oracle - Fri, 03 May 2013 07:37